MUC16 and neoplasm: For example, the MUC16:M9903I mutation mentioned previously shows a significant MAF increase from the primary site to the metastatic site in both tumor samples (from 6.3% in P042_PRI to 27% in P042_LIV) and in xenografts (from 10% in P042_PRI_PDX to 37% in P042_LIV_PDX).